Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

NCT03805932 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

NIH

Sponsor class

Conditions

Hairy Cell Leukemia

Interventions

DRUG: Moxetumomab Pasudotox-tdfk
BIOLOGICAL: Rituximab
BIOLOGICAL: Ruxience
DRUG: Dexamethasone
DRUG: Acetaminophen
DRUG: Diphenhydramine
DRUG: Famotidine
DRUG: Aspirin

Sponsor

National Cancer Institute (NCI)